Potential of Forsythiae Fructus in Mitigating Chemotherapy-Induced Gastrointestinal Inflammation and Nausea

December 19, 2023 10:52 PM AEDT | By EIN Presswire

Google News:

Potential of Forsythiae Fructus in Mitigating Chemotherapy-Induced Gastrointestinal Inflammation and Nausea — Image source: EIN Presswire

Recent News

Acorn Secures $12.3 Million to Reimagine Workforce Development with AI

Blue Yonder Survey: Consumers Shift Grocery Shopping Habits Amid Mount...

Performance Review Crisis: 80% of Leaders Say Employees Must Quit to A...

Vasion Delivers Security, Simplicity and Sustainability to Print Manag...

CHINA, December 19, 2023 /EINPresswire.com/ -- The authors of this study verified that Forsythiae Fructus and Forsythrin A and phillyrin has a therapeutic effect on CINV, and it also provides a reference treatment for the management of CINV.

Chemotherapy-induced nausea and vomiting (CINV) are among the most prevalent and distressing side effects faced by patients undergoing antineoplastic treatments. This condition can lead to complications such as dehydration, metabolic imbalances, anorexia and weakened physical stamina. Notably, highly emetic drugs such as cisplatin are notorious for causing severe nausea and vomiting in approximately 90% of patients. Therefore, enhancing the management of CINV is of utmost importance.

Chemotherapy-induced inflammation in the gastrointestinal tract is considered one of the potential pathological mechanisms of CINV. Forsythiae Fructus, or “lian qiao” in Chinese, has diverse biological activities, including antiemetic, anti-inflammatory, antioxidant, antiviral and neuroprotective properties. Derived from the dried fruit of Forsythia suspensa (Thunb.) Vahl, Forsythiae Fructus is a frequently used traditional Chinese medicine.

In a new study published in the Journal of Holistic Integrative Pharmacy, a team of researchers from the Guangdong Pharmaceutical University found that Forsythiae Fructus has CINV-attenuating properties. The researchers aimed to investigate the mechanism of chemotherapy-induced gastrointestinal inflammatory injury, focusing on epithelial cells pyroptosis using cisplatin-treated IEC-6 cells.

“Upon cisplatin stimulation, we observed an increase in ROS production and the activation and assembly of NLRP3 inflammasome,” shares Ke Nie, corresponding author of the study. “Once activated, the NLRP3 inflammasome recruit procaspase-1, leading to its activation, cleavage of GSDMD and subsequent formation of membrane pores. HMGB1 was released through these pores.”

Taken together, the findings indicate a strong connection between the development of gastrointestinal inflammation and intestinal epithelial cell pyroptosis induced by cisplatin. The researchers also evaluated the toxicity of cisplatin and LPS/ATP on J774A.1 macrophages and assessed the protective effect of Forsythiae Fructus extract, with results consistent with the aforementioned observations.

“Our study supports the idea that alleviating chemotherapy-induced gastrointestinal inflammation is a promising therapeutic approach against CINV,” says Nie. “Mechanistically, we found that the alleviating effect of Forsythiae Fructus and its primary components, phillyrin and forsythoside A, against cisplatin-induced cytotoxicity may be attributed to inhibiting oxidative stress, downregulating the NLRP3/caspase-1/GSDMD pathway, and inhibiting pyroptosis.”

DOI
10.1016/j.jhip.2023.09.001

Original Source URL
https://doi.org/10.1016/j.jhip.2023.09.001

Funding information
This work was supported by the Innovative Team Project of Ordinary Universities in Guangdong Province (No.2022KCXTD016) and the Key Subject Research Projects of Guangdong Province in 2019 (No.2019GDXK-0011).

Lucy Wang
BioDesign Research
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.